Sacubitril/Valsartan for the Prevention and Treatment of Postinfarction Heart Failure: Ready to Use?

J Cardiovasc Pharmacol. 2021 Sep 1;78(3):331-333. doi: 10.1097/FJC.0000000000001103.

Authors

Affiliations

¹ Department of Internal Medicine, Virginia Commonwealth University, Pauley Heart Center, Division of Cardiology, Richmond, VA.
² Department of Cardiovascular and Thoracic Sciences, Catholic University of the Sacred Heart, Rome, Italy.
³ Department of Hemodynamics and Interventional Cardiology, Hospital Italiano de Buenos Aires, Argentina; and.
⁴ Virginia Commonwealth University School of Pharmacy, Virginia Commonwealth University, Richmond, VA.

PMID: 34225338
DOI: 10.1097/FJC.0000000000001103

No abstract available

Publication types

Editorial

MeSH terms

Aminobutyrates / adverse effects
Aminobutyrates / therapeutic use*
Angiotensin II Type 1 Receptor Blockers / adverse effects
Angiotensin II Type 1 Receptor Blockers / therapeutic use*
Animals
Biphenyl Compounds / adverse effects
Biphenyl Compounds / therapeutic use*
Clinical Decision-Making
Disease Models, Animal
Drug Combinations
Evidence-Based Medicine
Heart Disease Risk Factors
Heart Failure / diagnosis
Heart Failure / mortality
Heart Failure / prevention & control*
Humans
Myocardial Infarction / diagnosis
Myocardial Infarction / drug therapy*
Myocardial Infarction / mortality
Neprilysin / antagonists & inhibitors
Protease Inhibitors / adverse effects
Protease Inhibitors / therapeutic use*
Protective Factors
Risk Assessment
Treatment Outcome
Valsartan / adverse effects
Valsartan / therapeutic use*

Substances

Aminobutyrates
Angiotensin II Type 1 Receptor Blockers
Biphenyl Compounds
Drug Combinations
Protease Inhibitors
Valsartan
Neprilysin
sacubitril and valsartan sodium hydrate drug combination